Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 984024, 11 pages
http://dx.doi.org/10.1155/2012/984024
Research Article

Renal Protective Effect of Xiao-Chai-Hu-Tang on Diabetic Nephropathy of Type 1-Diabetic Mice

1School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan
3Department of Pediatrics, IWK Health Centre, Halifax, NS, Canada B3K 6R8
4Institute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan 71101, Taiwan
5Department of Anesthesiology, Chi Mei Medical Center, Tainan 710, Taiwan
6Department of Anesthesiology, College of Medicine, Taipei Medical University, Taipei 110, Taiwan

Received 22 October 2011; Accepted 20 December 2011

Academic Editor: Angelo Antonio Izzo

Copyright © 2012 Chun-Ching Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. P. Schena and L. Gesualdo, “Pathogenetic mechanisms of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 3, supplement, pp. S30–S33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Rossing, “Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history,” Current Diabetes Reports, vol. 6, no. 6, pp. 479–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Bailey, “ACE inhibitors vs. ARBs for patients with diabetic kidney disease,” American Family Physician, vol. 76, no. 1, pp. 68–69, 2007. View at Google Scholar · View at Scopus
  4. S. I. Yamagishi, K. Fukami, S. Ueda, and S. Okuda, “Molecular mechanisms of diabetic nephropathy and its therapeutic intervention,” Current Drug Targets, vol. 8, no. 8, pp. 952–959, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D. LeRoith and E. J. Rayfield, “The benefits of tight glycemic control in type 2 diabetes mellitus,” Clinical Cornerstone, vol. 8, no. 7, pp. S19–S29, 2007. View at Google Scholar · View at Scopus
  6. Y. S. Kanwar, J. Wada, L. Sun et al., “Diabetic nephropathy: mechanisms of renal disease progression,” Experimental Biology and Medicine, vol. 233, no. 1, pp. 4–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Koya, K. Hayashi, M. Kitada, A. Kashiwagi, R. Kikkawa, and M. Haneda, “Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats,” Journal of the American Society of Nephrology, vol. 14, no. 3, supplement, pp. S250–S253, 2003. View at Google Scholar · View at Scopus
  8. S. Prabhakar, J. Starnes, S. Shi, B. Lonis, and R. Tran, “Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2945–2952, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Lehmann and E. D. Schleicher, “Molecular mechanism of diabetic nephropathy,” Clinica Chimica Acta, vol. 297, no. 1-2, pp. 135–144, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. J. T. Cheng, C. H. Yeh, C. K. Chang, M. F. Cheng, and H. J. Lin, “Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats,” Hormone and Metabolic Research, vol. 41, no. 8, pp. 605–611, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. N. Wang, J. Lapage, and R. Hirschberg, “Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 12, no. 11, pp. 2392–2399, 2001. View at Google Scholar · View at Scopus
  12. C. H. Yeh, C. K. Chang, M. F. Cheng, H. J. Lin, and J. T. Cheng, “The antioxidative effect of bone morphogenetic protein-7 against high glucose-induced oxidative stress in mesangial cells,” Biochemical and Biophysical Research Communications, vol. 382, no. 2, pp. 292–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Ohta, K. Nishida, E. Sasaki et al., “Comparative study of oral and parenteral administration of sho-saiko-to (xiao-chaihu-tang) extract on d-galactosamine-induced liver injury in rats,” American Journal of Chinese Medicine, vol. 25, no. 3-4, pp. 333–342, 1997. View at Google Scholar · View at Scopus
  14. M. Yamashiki, A. Nishimura, H. Suzuki, S. Sakaguchi, and Y. Kosaka, “Effects of the Japanese herbal medicine “Sho-saiko-to” (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C,” Hepatology, vol. 25, no. 6, pp. 1390–1397, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Yamashiki, A. Nishimura, T. Nobori et al., “In vitro effects of Sho-saiko-to on production of granulocyte colony- stimulating factor by mononuclear cells from patients with chronic hepatitis C,” International Journal of Immunopharmacology, vol. 19, no. 7, pp. 381–385, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. X. X. Huang, M. Yamashiki, K. Nakatani, T. Nobori, and A. Mase, “Semi-quantitative analysis of cytokine mRNA expression induced by the herbal medicine Sho-saiko-to (TJ-9) using a gel doc system,” Journal of Clinical Laboratory Analysis, vol. 15, no. 4, pp. 199–209, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Shiota, Y. Maeta, T. Mukoyama et al., “Effects of Sho-saiko-to on hepatocarcinogenesis and 8-hydroxy-2-deoxyguanosine formation,” Hepatology, vol. 35, no. 5, pp. 1125–1133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. T. Borchers, S. Sakai, G. L. Henderson et al., “Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities,” Journal of Ethnopharmacology, vol. 73, no. 1-2, pp. 1–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Kayano, I. Sakaida, K. Uchida, and K. Okita, “Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells,” Journal of Hepatology, vol. 29, no. 4, pp. 642–649, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Shimizu, Y. R. Ma, Y. Mizobuchi et al., “Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats,” Hepatology, vol. 29, no. 1, pp. 149–160, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ono, M. Miyamura, S. Kyotani, T. Saibara, S. Ohnishi, and Y. Nishioka, “Effect of Sho-saiko-to extract on HGF and TGF-β levels of intraorgans in liver-injured rats after partial hepatectomy,” Journal of Pharmacy and Pharmacology, vol. 52, no. 1, pp. 111–118, 2000. View at Google Scholar · View at Scopus
  22. K. Hayashi, R. Kojima, and M. Ito, “Strain differences in the diabetogenic activity of streptozotocin in mice,” Biological and Pharmaceutical Bulletin, vol. 29, no. 6, pp. 1110–1119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. W. A. Border, S. Okuda, L. R. Languino, M. B. Sporn, and E. Ruoslahti, “Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1,” Nature, vol. 346, no. 6282, pp. 371–374, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. J. T. Cheng, C. C. Huang, I. M. Liu, T. F. Tzeng, and J. C. Chih, “Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats,” Diabetes, vol. 55, no. 3, pp. 819–825, 2006. View at Google Scholar · View at Scopus
  25. M. P. Cohen and C. V. Klein, “Glomerulopathy in rats with streptozotocin diabetes. Accumulation of glomerular basement membrane analogous to human diabetic nephropathy,” Journal of Experimental Medicine, vol. 149, no. 3, pp. 623–631, 1979. View at Google Scholar · View at Scopus
  26. S. M. Mauer, M. W. Steffes, and D. M. Brown, “The kidney in diabetes,” American Journal of Medicine, vol. 70, no. 3, pp. 603–612, 1981. View at Google Scholar · View at Scopus
  27. A. J. Fowell and J. P. Iredale, “Emerging therapies for liver fibrosis,” Digestive Diseases, vol. 24, no. 1-2, pp. 174–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. W. B. Reeves and T. E. Andreoli, “Transforming growth factor β contributes to progressive diabetic nephropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 7667–7669, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. T. A. McGowan, Y. Zhu, and K. Sharma, “Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy,” Current Diabetes Reports, vol. 4, no. 6, pp. 447–454, 2004. View at Google Scholar · View at Scopus
  30. M. H. Chen, J. C. Chen, C. C. Tsai et al., “The role of TGF-β1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model,” Journal of Ethnopharmacology, vol. 97, no. 1, pp. 7–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. H. Chen, J. C. Chen, C. C. Tsai et al., “Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats,” American Journal of Chinese Medicine, vol. 32, no. 2, pp. 195–207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Xia, H. Wang, S. Munk et al., “High glucose activates PKC-ζ and NADPH oxidase through autocrine TGF-β1 signaling in mesangial cells,” American Journal of Physiology, vol. 295, no. 6, pp. F1705–F1714, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Ha and H. B. Lee, “Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney,” Nephrology, vol. 10, no. 2, supplement, pp. S7–S10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Kaneko, H. Chiba, N. Horie et al., “Effect of two different groups of Chinese medicines on nitric oxide production by mouse macrophage-like cells,” In Vivo, vol. 18, no. 6, pp. 771–778, 2004. View at Google Scholar · View at Scopus
  35. S. Klahr and J. Morrissey, “Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor,” Kidney International, vol. 64, no. 87, supplement, pp. S105–S112, 2003. View at Google Scholar · View at Scopus
  36. Y. Ikeda, Y. O. Jung, H. Kim et al., “Exogenous bone morphogenetic protein-7 fails to attenuate renal fibrosis in rats with overload proteinuria,” Nephron, vol. 97, no. 4, pp. e123–e135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J.-T. Cheng, C.-H. Yeh, C.-K. Chang, K.-C. Cheng, Y.-X. Li, and Y. W. Zhang, “Role of bone morphogenetic proteins-7 (BMP-7) in the renal improvement effect of DangGui (Angelica sinensis) in type-1 diabetic rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 796723, 9 pages, 2011. View at Publisher · View at Google Scholar